Faeth Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics, Inc., trading under Nasdaq: FTH) is a clinical-stage biotechnology company pioneering multi-node inhibition of the PI3K/AKT/mTOR (PAM) pathway, which is the most frequently altered oncogenic pathway in cancer. The company's therapeutic approach focuses on overcoming the limitations of single-node inhibitors, which historically trigger feedback loops and resistance, by simultaneously targeting multiple nodes of the pathway. Faeth's lead clinical program is PIKTOR, an investigational all-oral combination of serabelisib (a selective PI3K-alpha inhibitor) and sapanisertib (a dual mTORC1/2 inhibitor). Originally founded in 2019 to target tumor metabolism through a combination of precision therapeutics and genotype-guided dietary interventions, the company transitioned to a publicly traded entity in February 2026 via an acquisition by Sensei Biotherapeutics, which subsequently rebranded as Faeth Therapeutics, Inc. in June 2026.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing PIKTOR, an all-oral combination of serabelisib (PI3K-alpha inhibitor) and sapanisertib (mTORC1/2 inhibitor), designed to simultaneously target three nodes of the PI3K/AKT/mTOR (PAM) pathway to prevent tumor escape and resistance mechanisms.
Expected impact: Establishes a highly differentiated, oral oncology regimen targeting one of the most frequently altered pathways in cancer, potentially offering superior efficacy and tolerability compared to single-node inhibitors.
Following the acquisition of Faeth Therapeutics by Sensei Biotherapeutics, the combined company executed a complete corporate rebranding, changing its name to Faeth Therapeutics, Inc., updating its Nasdaq ticker to 'FTH', and shifting its primary strategic focus to Faeth's clinical-stage oncology pipeline.
Expected impact: Aligns the corporate identity with the newly acquired lead asset PIKTOR, streamlining investor relations and focusing organizational resources on the high-potential cancer metabolism pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
The transaction structured as a stock-for-stock reverse merger brought Faeth's lead asset PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, into the combined company's pipeline. It allowed the private startup Faeth to go public, while providing Sensei with a highly promising clinical-stage oncology asset and a major capital infusion from a concurrent private placement.
Financial impact: The transaction was accompanied by a concurrent $200 million private placement of Series B preferred stock from leading life sciences investors, significantly strengthening the company's balance sheet to fund clinical trials through key milestones.